The logo of Swiss specialty chemicals company Clariant is seen at the company’s headquarters in Pratteln, Switzerland October 29, 2017. REUTERS/Arnd Wiegmann
October 30, 2017
ZURICH (Reuters) – Activist investor White Tale on Monday demanded three seats on Clariant’s board and an independent strategic review of the Swiss speciality chemicals group after thwarting its plans to merge with U.S. peer Huntsman in a $20 billion deal.
“Should we be unable to come to agreement with the current board of directors shortly, we will have no choice but to move to call an extraordinary general meeting so that all shareholders can have a voice in Clariant’s future,” the activist that holds a stake of more than 20 percent said.
(Reporting by John Miller, Editing by Michael Shields)
